BeiGene, Ltd. (BGNE)

156.53 +2.59 (+1.68%) At close: 04:00PM EDT

BeiGene, Ltd.

94 Solaris Avenue
Camana Bay
Grand Cayman KY1-1108
Cayman Islands
345 949 4123
https://www.beigene.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10,600

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John V. Oyler	Co-Founder, Executive Chairman & CEO	2.43M	N/A	1968
Dr. Xiaobin Wu Ph.D.	President & COO	1.7M	N/A	1962
Mr. Yang Ji	Chief Compliance Officer	N/A	N/A	N/A
Dr. Yan Qi	Senior VP & Head of Public Affairs - Greater China	N/A	N/A	N/A
Mr. Jason W. Radford	Senior Vice President of Strategy & Corporate Development	N/A	N/A	1982
Dr. Mark Lanasa	Senior VP & Chief Medical Officer for Solid Tumors	N/A	N/A	N/A
Mr. Graham Hardiman	Global Head of Human Resources	N/A	N/A	N/A
Mr. Luo Lusong Ph.D.	Head of External Innovation & Senior VP	N/A	N/A	N/A
Dr. Steven Young	Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Wang Zhiwei Ph.D.	Research Head of Chemistry & Senior VP	N/A	N/A	1971

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Corporate governance

BeiGene, Ltd.’s ISS governance QualityScore as of 29 April 2024 is 7. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.